SMT launches next generation Supralimus Grace drug eluting stent in India

Mumbai: SMT, One of the largest stent manufacturing company in India, has recently announced the launch and widespread availability plans for its next-generation Supralimus Grace™ Sirolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

Fourth Generation Stent System, Supralimus Grace presents better deliverability, upgraded technology, enhanced balloon features and cutting edge shaft welding technology. Pioneer of Biodegradable Polymer technology, SMT is the largest Indian company in angioplasty devices space with more than 7500 implantations a month as on September, 2017.

Supralimus Grace is an advanced Drug Eluting stent system (DES) which features fourth generation design with next generation balloon, presenting unique attributes such as biodegradable polymer coating of which SMT is a pioneer. Supralimus Grace also has lowest strut thickness of 60µ which is a vital for the outcomes of the treatment success. Strut thickness has direct co-relation with re-blockage phenomenon.

Supralimus Grace has recently been introduced in 20 hospitals. Going forward, the company has plans to make this latest technology brand available at more than 400 centres in the next 3 months. In line with SMT’s vision i.e. ‘Pledged to Save Millions’ we are also committed to join hands with the agenda of Indian Government which envisage the extension of life for Indian patients with latest generation products.

"The extraordinary deliverability of the new Supralimus Grace DES System allows physicians to treat complex coronary disease with great ease and confidence," Said Mr. Piyush Savalia, Sr. VP Marketing and Clinical Trials, SMT. He also added,

“SMT’s Proprietary technology for Rx Joint welding ensures minimal loss of force and improves pushability which is essential for treating complex coronary disease. The balloon material has been further improvised for faster & low deflation profile for smoother experience while retrieving the stent delivery system, post stent dilation. Another remarkable feature is the Link between transition of hard shaft and soft shaft which is engineered to have a kink free experience.”

Backed up by strong R & D efforts, SMT is globally the first company to receive CE approval for DES with biodegradable polymers. Lack of demographic clinical evidence on Indian patients has always been a lacuna. With highest number of clinical data on Indian patients, SMT has addressed this much-needed aspect. Clinical trial portfolio of SMT has captured more than 15,000 patients published data in reputed indexed journals.

Meaningful innovation coupled with unmatched quality & excellence has helped SMT achieve the stellar performance on market front. SMT is among top three leading medical devices companies in India with focus on cardiovascular devices space. The company has doubled its market share in last three years. Cardiovascular devices market has grown by 10-12 % on volume parameter whereas SMT has been a bright spot with volume growth achievement of above 40% at CAGR in last three years.